We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Evaluation of Wistar RA27/3 Rubella Virus Vaccine in Children

Henry H. Balfour Jr, MD; Carol L. Balfour, RN; Charlene K. Edelman; Phillip A. Rierson, MD
Am J Dis Child. 1976;130(10):1089-1091. doi:10.1001/archpedi.1976.02120110051006.
Text Size: A A A
Published online


• Because the Wistar RA27/3 strain rubella virus vaccine has potentially important advantages over rubella vaccines currently licensed in the United States, a field trial was conducted in Minnesota and Wisconsin in 1974 to evaluate RA27/3 in this country. Two hundred eighty-five (99.7%) of 286 susceptible children given RA27/3 subcutaneously seroconverted, with a geometric mean hemagglutination inhibition (HI) titer of 81.2. Twenty-eight (23%) of 122 children with rubella antibodies before immunization had fourfold or greater rises in rubella HI titers. The highest percentage of booster responses occurred in children with low preimmunization titers. Side effects were reported in 34% of subjects, but only one reaction associated with RA27/3 was serious: in a 5-year-old boy, arthritis of the left hip developed 31 days after immunization. This study indicates that RA27/3 vaccine produced a very high rate of seroconversion with high postimmunization HI titers. The ability to elicit significant booster responses in children with low levels of HI antibodies suggests that RA27/3 could be used to boost immunity in women of childbearing age whose rubella titers have declined to undetectable levels.

(Am J Dis Child 130:1089-1091, 1976)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.